Is there a real alternative to weight loss injections?

Why do some people look for an alternative to injections?

Needle anxiety is the most common reason. For some people it is a genuine barrier, not squeamishness exactly, but a persistent reluctance that makes weekly self-injection feel unsustainable from the start. Others have practical concerns: travel, storage (injectable GLP-1 medicines need refrigeration), or jobs that make a consistent weekly ritual tricky. A smaller group has a medical reason (certain skin conditions at injection sites, for instance) and a few simply want to know all the options before committing to one.

None of these reasons is wrong. The question worth asking, though, is whether the alternative you are considering is genuinely equivalent, or whether you are trading efficacy for convenience. Our guide to weight loss injections covers what the injectable options involve day to day, which is useful context before comparing formats.

The honest answer is that injectables still have the longest evidence base. But that gap is closing, and for people who would not sustain an injection regimen, a tablet they will actually take consistently may deliver better real-world results than an injection they dread.

What does the oral alternative actually involve?

Wegovy tablets contain semaglutide (the same active molecule as the Wegovy injection) combined with an absorption enhancer that allows it to pass through the stomach lining. The MHRA approved it on 11 June 2026, making the UK the first country in Europe to license an oral GLP-1 for weight management. The NHS medicines page for semaglutide explains how semaglutide works at a patient level.

The dosing schedule starts at 1.5 mg daily and steps up through 4 mg and 9 mg to a 25 mg maintenance dose, with at least a month at each level. Taking it correctly matters more than with an injection: first thing in the morning, on a completely empty stomach, with a small amount of plain water, then nothing else (no coffee, no food, no other oral medicines) for at least 30 minutes. That 30-minute window is the practical habit to build into your day.

In the phase 3 OASIS 4 trial (307 adults, 64 weeks, no diabetes), participants lost an average of around 13.6% of their body weight compared with around 2.4% on placebo. Among those who adhered fully to treatment, average loss reached roughly 17%. No refrigeration is needed, which removes one of the logistical headaches of injectable treatment. If you want to understand how effective weight loss injections are before choosing a format, our dedicated page on that question sits alongside the efficacy data for a balanced view.

Are injectables still worth considering if you dislike needles?

Worth considering, yes, especially before ruling them out entirely. The needles used for Mounjaro and Wegovy are very fine and short; most people who expected the worst find the reality manageable after the first or second pen. There is a useful, practical check you can do in under a minute: look at the step-by-step injection guide on our site, which walks through exactly what the process looks like. Some people read it and realise the barrier was mainly the unknown.

Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist (the only medicine in the UK that activates both pathways) and its trial results are the strongest available for any licensed weight-loss medicine, with average body-weight reductions of around 20–21% at the highest dose in SURMOUNT-1. NICE's appraisal of tirzepatide (TA1026) sets out the clinical evidence behind that recommendation. Wegovy injection, at the 2.4 mg dose, showed around 15% average loss over 68 weeks in STEP 1.

If needle anxiety is the issue rather than a hard contraindication, it may be worth discussing with a prescriber before defaulting to the oral route. Our weight loss injection overview sets out the practical details of both injectable options side by side.

What about older oral options like orlistat?

Orlistat has been available in the UK for many years and works entirely differently from GLP-1 medicines: it blocks the enzyme that digests dietary fat, so roughly a third of the fat you eat passes through unabsorbed. It does not affect appetite hormones. Prescription-strength orlistat (120 mg, three times daily with meals) typically produces modest weight loss, meaningful for some people, but generally less than the newer GLP-1 options in head-to-head terms.

The side-effect profile also differs: because undigested fat reaches the bowel, oily stools, urgency, and flatulence are common, particularly if fat intake is high. Keeping dietary fat low reduces these effects significantly, which means orlistat works partly by disincentivising high-fat eating. It is a legitimate option for some people, but it suits a fairly specific profile, someone who tolerates the GI effects, is motivated to adjust their diet carefully, and for whom GLP-1 medicines are not suitable. If you are also thinking through the negative effects that weight loss injections can bring, our dedicated page covers the full picture so you can weigh up tolerability across formats.

For anyone weighing up the full landscape of weight loss treatments available privately in the UK, it is useful to understand that orlistat, oral semaglutide, and injectable GLP-1 medicines all sit in different places on the efficacy and tolerability spectrum. Cost context is also part of the picture, our page on cost and pricing for weight loss injections covers what you can typically expect to pay.